HSD55 Non-Interventional, Real-World Study of Patients with Early Stage, Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Receiving Biosimilar Trastuzumab
Jul 1, 2022, 00:00
10.1016/j.jval.2022.04.1056
https://www.valueinhealthjournal.com/article/S1098-3015(22)01257-8/fulltext
Title :
HSD55 Non-Interventional, Real-World Study of Patients with Early Stage, Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Receiving Biosimilar Trastuzumab
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)01257-8&doi=10.1016/j.jval.2022.04.1056
First page :
Section Title :
Open access? :
No
Section Order :
10948